Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
11
CUE Quote, Financials, Valuation and Earnings
Last price:
$0.24
Seasonality move
:
-5.96%
Day range:
$0.23 - $0.25
52-week range:
$0.23 - $1.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.93x
P/B ratio:
1.43x
Volume:
725.1K
Avg. volume:
656.8K
1-year change:
-76.14%
Market cap:
$19M
Revenue:
$9.3M
EPS (TTM):
-$0.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CUE
Cue Biopharma, Inc.
|
$2.3M | -$0.09 | 11.04% | -21.81% | $5.00 |
|
ADPT
Adaptive Biotechnologies Corp.
|
$64.6M | -$0.14 | 24.92% | -21.12% | $19.86 |
|
INSM
Insmed, Inc.
|
$115.5M | -$1.37 | 66.86% | -2.57% | $214.78 |
|
MRSN
Mersana Therapeutics, Inc.
|
$13.7M | -$0.89 | -69.75% | -14.49% | $33.20 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PBYI
Puma Biotechnology, Inc.
|
$51M | $0.09 | 16.12% | -41.13% | $3.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CUE
Cue Biopharma, Inc.
|
$0.24 | $5.00 | $19M | -- | $0.00 | 0% | 2.93x |
|
ADPT
Adaptive Biotechnologies Corp.
|
$16.68 | $19.86 | $2.5B | -- | $0.00 | 0% | 10.10x |
|
INSM
Insmed, Inc.
|
$177.42 | $214.78 | $37.8B | -- | $0.00 | 0% | 75.50x |
|
MRSN
Mersana Therapeutics, Inc.
|
$29.10 | $33.20 | $145.1M | -- | $0.00 | 0% | 56.57x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
PBYI
Puma Biotechnology, Inc.
|
$5.96 | $3.50 | $300.3M | 8.05x | $0.00 | 0% | 1.41x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CUE
Cue Biopharma, Inc.
|
31.79% | 2.492 | 11.04% | 1.23x |
|
ADPT
Adaptive Biotechnologies Corp.
|
51.1% | 3.094 | 9.36% | 3.09x |
|
INSM
Insmed, Inc.
|
44.07% | 2.512 | 2.43% | 4.18x |
|
MRSN
Mersana Therapeutics, Inc.
|
-4.01% | -0.289 | 5.93% | 1.32x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 1.268 | 15.34% | 1.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CUE
Cue Biopharma, Inc.
|
$2.1M | -$7.5M | -156.79% | -233.04% | -351.05% | -$9M |
|
ADPT
Adaptive Biotechnologies Corp.
|
$72.6M | $10.3M | -18.96% | -39.8% | 10.95% | -$7.5M |
|
INSM
Insmed, Inc.
|
$111.4M | -$261.4M | -70.98% | -193.23% | -183.61% | -$222.2M |
|
MRSN
Mersana Therapeutics, Inc.
|
$10.9M | -$7.5M | -689.85% | -533.43% | -67.68% | -$3.2M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
Cue Biopharma, Inc. vs. Competitors
-
Which has Higher Returns CUE or ADPT?
Adaptive Biotechnologies Corp. has a net margin of -346.58% compared to Cue Biopharma, Inc.'s net margin of 10.16%. Cue Biopharma, Inc.'s return on equity of -233.04% beat Adaptive Biotechnologies Corp.'s return on equity of -39.8%.
Company Gross Margin Earnings Per Share Invested Capital CUECue Biopharma, Inc.96.32% -$0.07 $19.4M ADPTAdaptive Biotechnologies Corp.77.3% $0.06 $417.9M -
What do Analysts Say About CUE or ADPT?
Cue Biopharma, Inc. has a consensus price target of $5.00, signalling upside risk potential of 1974.69%. On the other hand Adaptive Biotechnologies Corp. has an analysts' consensus of $19.86 which suggests that it could grow by 18.55%. Given that Cue Biopharma, Inc. has higher upside potential than Adaptive Biotechnologies Corp., analysts believe Cue Biopharma, Inc. is more attractive than Adaptive Biotechnologies Corp..
Company Buy Ratings Hold Ratings Sell Ratings CUECue Biopharma, Inc.2 0 0 ADPTAdaptive Biotechnologies Corp.5 1 0 -
Is CUE or ADPT More Risky?
Cue Biopharma, Inc. has a beta of 1.393, which suggesting that the stock is 39.251% more volatile than S&P 500. In comparison Adaptive Biotechnologies Corp. has a beta of 2.201, suggesting its more volatile than the S&P 500 by 120.134%.
-
Which is a Better Dividend Stock CUE or ADPT?
Cue Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptive Biotechnologies Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma, Inc. pays -- of its earnings as a dividend. Adaptive Biotechnologies Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CUE or ADPT?
Cue Biopharma, Inc. quarterly revenues are $2.1M, which are smaller than Adaptive Biotechnologies Corp. quarterly revenues of $94M. Cue Biopharma, Inc.'s net income of -$7.4M is lower than Adaptive Biotechnologies Corp.'s net income of $9.5M. Notably, Cue Biopharma, Inc.'s price-to-earnings ratio is -- while Adaptive Biotechnologies Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma, Inc. is 2.93x versus 10.10x for Adaptive Biotechnologies Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CUECue Biopharma, Inc.2.93x -- $2.1M -$7.4M ADPTAdaptive Biotechnologies Corp.10.10x -- $94M $9.5M
-
Which has Higher Returns CUE or INSM?
Insmed, Inc. has a net margin of -346.58% compared to Cue Biopharma, Inc.'s net margin of -259.95%. Cue Biopharma, Inc.'s return on equity of -233.04% beat Insmed, Inc.'s return on equity of -193.23%.
Company Gross Margin Earnings Per Share Invested Capital CUECue Biopharma, Inc.96.32% -$0.07 $19.4M INSMInsmed, Inc.78.29% -$1.75 $1.7B -
What do Analysts Say About CUE or INSM?
Cue Biopharma, Inc. has a consensus price target of $5.00, signalling upside risk potential of 1974.69%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 21.15%. Given that Cue Biopharma, Inc. has higher upside potential than Insmed, Inc., analysts believe Cue Biopharma, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CUECue Biopharma, Inc.2 0 0 INSMInsmed, Inc.17 1 0 -
Is CUE or INSM More Risky?
Cue Biopharma, Inc. has a beta of 1.393, which suggesting that the stock is 39.251% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.
-
Which is a Better Dividend Stock CUE or INSM?
Cue Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CUE or INSM?
Cue Biopharma, Inc. quarterly revenues are $2.1M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Cue Biopharma, Inc.'s net income of -$7.4M is higher than Insmed, Inc.'s net income of -$370M. Notably, Cue Biopharma, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma, Inc. is 2.93x versus 75.50x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CUECue Biopharma, Inc.2.93x -- $2.1M -$7.4M INSMInsmed, Inc.75.50x -- $142.3M -$370M
-
Which has Higher Returns CUE or MRSN?
Mersana Therapeutics, Inc. has a net margin of -346.58% compared to Cue Biopharma, Inc.'s net margin of -68.54%. Cue Biopharma, Inc.'s return on equity of -233.04% beat Mersana Therapeutics, Inc.'s return on equity of -533.43%.
Company Gross Margin Earnings Per Share Invested Capital CUECue Biopharma, Inc.96.32% -$0.07 $19.4M MRSNMersana Therapeutics, Inc.99.25% -$1.51 -$57.2M -
What do Analysts Say About CUE or MRSN?
Cue Biopharma, Inc. has a consensus price target of $5.00, signalling upside risk potential of 1974.69%. On the other hand Mersana Therapeutics, Inc. has an analysts' consensus of $33.20 which suggests that it could grow by 14.09%. Given that Cue Biopharma, Inc. has higher upside potential than Mersana Therapeutics, Inc., analysts believe Cue Biopharma, Inc. is more attractive than Mersana Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CUECue Biopharma, Inc.2 0 0 MRSNMersana Therapeutics, Inc.0 7 0 -
Is CUE or MRSN More Risky?
Cue Biopharma, Inc. has a beta of 1.393, which suggesting that the stock is 39.251% more volatile than S&P 500. In comparison Mersana Therapeutics, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.856%.
-
Which is a Better Dividend Stock CUE or MRSN?
Cue Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mersana Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma, Inc. pays -- of its earnings as a dividend. Mersana Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CUE or MRSN?
Cue Biopharma, Inc. quarterly revenues are $2.1M, which are smaller than Mersana Therapeutics, Inc. quarterly revenues of $11M. Cue Biopharma, Inc.'s net income of -$7.4M is higher than Mersana Therapeutics, Inc.'s net income of -$7.5M. Notably, Cue Biopharma, Inc.'s price-to-earnings ratio is -- while Mersana Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma, Inc. is 2.93x versus 56.57x for Mersana Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CUECue Biopharma, Inc.2.93x -- $2.1M -$7.4M MRSNMersana Therapeutics, Inc.56.57x -- $11M -$7.5M
-
Which has Higher Returns CUE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -346.58% compared to Cue Biopharma, Inc.'s net margin of -255.85%. Cue Biopharma, Inc.'s return on equity of -233.04% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital CUECue Biopharma, Inc.96.32% -$0.07 $19.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About CUE or NBY?
Cue Biopharma, Inc. has a consensus price target of $5.00, signalling upside risk potential of 1974.69%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Cue Biopharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cue Biopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CUECue Biopharma, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is CUE or NBY More Risky?
Cue Biopharma, Inc. has a beta of 1.393, which suggesting that the stock is 39.251% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock CUE or NBY?
Cue Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cue Biopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CUE or NBY?
Cue Biopharma, Inc. quarterly revenues are $2.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cue Biopharma, Inc.'s net income of -$7.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cue Biopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma, Inc. is 2.93x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CUECue Biopharma, Inc.2.93x -- $2.1M -$7.4M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns CUE or PBYI?
Puma Biotechnology, Inc. has a net margin of -346.58% compared to Cue Biopharma, Inc.'s net margin of 16.24%. Cue Biopharma, Inc.'s return on equity of -233.04% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital CUECue Biopharma, Inc.96.32% -$0.07 $19.4M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About CUE or PBYI?
Cue Biopharma, Inc. has a consensus price target of $5.00, signalling upside risk potential of 1974.69%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -41.28%. Given that Cue Biopharma, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Cue Biopharma, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CUECue Biopharma, Inc.2 0 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is CUE or PBYI More Risky?
Cue Biopharma, Inc. has a beta of 1.393, which suggesting that the stock is 39.251% more volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.
-
Which is a Better Dividend Stock CUE or PBYI?
Cue Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cue Biopharma, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CUE or PBYI?
Cue Biopharma, Inc. quarterly revenues are $2.1M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Cue Biopharma, Inc.'s net income of -$7.4M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Cue Biopharma, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cue Biopharma, Inc. is 2.93x versus 1.41x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CUECue Biopharma, Inc.2.93x -- $2.1M -$7.4M PBYIPuma Biotechnology, Inc.1.41x 8.05x $54.5M $8.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
